
Indivior PLC (INDV) Stock Forecast & Price Target
Indivior PLC (INDV) Analyst Ratings
Bulls say
Indivior PLC has raised its 2025 revenue guidance for Sublocade to a range of $765 million to $786 million, indicating positive momentum due to continued volume growth and targeted efforts in the Medicaid and commercial patient segments. The company stands as a leader in the treatment of substance use disorders, poised to capitalize on the increasing adoption of Medication-Assisted Treatments (MATs) amid growing public awareness and diminishing stigma surrounding addiction treatment. Furthermore, while competitors like Brixadi have gained market share, Sublocade's market share has stabilized, reinforcing Indivior's strong position in a growing market.
Bears say
Indivior PLC faces significant revenue challenges as the decline in Suboxone sales, attributed to increasing generic competition, is expected to continue, raising concerns about the company's overall financial stability. Although Sublocade shows potential for growth in the long-acting injectable (LAI) category, it is still early in its commercial lifecycle and may not sufficiently counterbalance the ongoing Suboxone revenue erosion. Furthermore, the projected increase in selling, general and administrative (SG&A) expenses to 45% of revenue in 2026, while a slight improvement from 2025, indicates persistent operational cost challenges that could further impact profitability.
This aggregate rating is based on analysts' research of Indivior PLC and is not a guaranteed prediction by Public.com or investment advice.
Indivior PLC (INDV) Analyst Forecast & Price Prediction
Start investing in Indivior PLC (INDV)
Order type
Buy in
Order amount
Est. shares
0 shares